Uncommon Bio vs Emulate
Side-by-side comparison of AI visibility scores, market position, and capabilities
Uncommon Bio (formerly Higher Steaks) pivoted from cultivated pork to therapeutic biomanufacturing in 2024–2025; its cultivated meat platform was acquired by Meatable in 2025; now focuses on scalable cell biology tools for human health applications.
About
Uncommon Bio (formerly Higher Steaks) is a UK-based biotechnology company that underwent a significant strategic pivot in 2024–2025, transitioning from cultivated meat production toward developing scalable biomanufacturing technologies for human therapeutic applications. Founded by Benjamina Bollag, the company was originally focused on developing cultivated pork products using cell culture and bioprocess engineering techniques. In 2025, Uncommon Bio's cultivated meat platform and associated intellectual property were acquired by Meatable, a Netherlands-based cultivated meat company — allowing Uncommon Bio to exit the food application space and redirect its biomanufacturing expertise toward the healthcare and therapeutics sector.
Pioneering organ-on-chip platform installed in 150+ labs including 17 of the top 25 biopharma companies; launched AVA™ high-throughput 96-chip system in 2025 and holds the only FDA ISTAND-accepted DILI Organ-Chip.
About
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the microstructure and function of human organs. Founded in 2013 as a spin-out from the Wyss Institute at Harvard University, Emulate's chips model the liver, intestine, lung, kidney, brain, and other organ systems with a fidelity that animal models and traditional cell culture cannot match. The technology was originally developed to reduce drug development attrition rates caused by poor translation from animal studies to human clinical outcomes.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.